Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial
Stem Cell Therapeutics Corp. (”SCT” or “the Company”) (TSX VENTURE:SSS) is pleased to announce the U.S. Food and Drug Administration (”FDA”) has provided a verbal confirmation to remove its clinical hold placed on NTx®-265 on September 18, 2008. This will allow SCT to commence the recruitment of patients under an amended protocol using NTx®-265 for the Company’s Phase IIb clinical trial treating acute ischemic stroke. Dr.
[Read the full article here]Related News:
FDA to lift clinical hold on Stem Cell Therapeutics' phase-IIb stroke trial
Stem Cell Therapeutics Corp. Receives Formal Clearance From the FDA to Proceed With Their Phase IIb Stroke Trial
DSMB recommends Stem Cell Therapeutics for phase-IIb acute ischemic stroke trial